Study on the Mechanism of Ginseng in the Treatment of Lung Adenocarcinoma Based on Network Pharmacology

Joint Authors

Zhang, Ping
Li, Qiu-Yue
Hou, Cheng-Zhi
Yang, Li-Ping
Chu, Xue-Lei
Wang, Yuan
Zhao, Yong

Source

Evidence-Based Complementary and Alternative Medicine

Issue

Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-11, 11 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2020-07-31

Country of Publication

Egypt

No. of Pages

11

Main Subjects

Medicine

Abstract EN

Background.

Ginseng, a traditional Chinese medicine, was used to prevent and treat many diseases such as diabetes, inflammation, and cancer.

In recent years, there are some reports about the treatment of lung adenocarcinoma with ginseng monomer compounds, but there is no systematic study on the related core targets and mechanism of ginseng in the treatment of lung adenocarcinoma up to now.

Therefore, this study systematically and comprehensively studied the molecular mechanism of ginseng in the treatment of lung adenocarcinoma based on network pharmacology and further proved the potential targets by A549 cell experiments for the first time.

Methods.

The targets of disease and drug were obtained from Gene database.

Subsequently, the compound-target network was constructed, and the core potential targets were screened out by plug-in into Cytoscape.

Furthermore, the core targets and mechanism of ginseng in the treatment of lung adenocarcinoma were verified by MTT test, cell scratch test, immunohistochemistry, and qRT-PCR.

Results.

1791 disease targets and 144 drug targets were obtained by searching the Gene database.

Meanwhile, 15 core targets were screened out: JUN, MAPK8, PTGS2, CASP3, VEGFA, MMP9, AKT1, TNF, FN1, FOS, MMP782, IL-1β, IL-2, ICAM1, and HMOX1.

The results of cell experiments indicate that ginseng could treat lung adenocarcinoma by cell proliferation, migration, and apoptosis.

In addition, according to the results of the 15 core targets by qRT-PCR, JUN, IL-1β, IL-2, ICAM1, HMOX1, MMP9, and MMP2 are upregulated core targets, while PTGS2 and TNF are downregulated core targets.

Conclusion.

This study systematically and comprehensively studied 15 core targets by network pharmacology for the first time.

Subsequently, it is verified that 9 core targets for ginseng treatment of lung adenocarcinoma, namely, JUN, IL-1β, IL-2, ICAM1, HMOX1, MMP9, MMP2, PTGS2, and TNF, are closely related to the proliferation, migration, and apoptosis of lung adenocarcinoma cells.

This study has reference value for the clinical application of ginseng in the treatment of lung adenocarcinoma.

American Psychological Association (APA)

Li, Qiu-Yue& Hou, Cheng-Zhi& Yang, Li-Ping& Chu, Xue-Lei& Wang, Yuan& Zhang, Ping…[et al.]. 2020. Study on the Mechanism of Ginseng in the Treatment of Lung Adenocarcinoma Based on Network Pharmacology. Evidence-Based Complementary and Alternative Medicine،Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1155335

Modern Language Association (MLA)

Li, Qiu-Yue…[et al.]. Study on the Mechanism of Ginseng in the Treatment of Lung Adenocarcinoma Based on Network Pharmacology. Evidence-Based Complementary and Alternative Medicine No. 2020 (2020), pp.1-11.
https://search.emarefa.net/detail/BIM-1155335

American Medical Association (AMA)

Li, Qiu-Yue& Hou, Cheng-Zhi& Yang, Li-Ping& Chu, Xue-Lei& Wang, Yuan& Zhang, Ping…[et al.]. Study on the Mechanism of Ginseng in the Treatment of Lung Adenocarcinoma Based on Network Pharmacology. Evidence-Based Complementary and Alternative Medicine. 2020. Vol. 2020, no. 2020, pp.1-11.
https://search.emarefa.net/detail/BIM-1155335

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-1155335